Strategic partnership Triplefin is now EVERSANA, a comprehensive life sciences commercialization platform. This presents an opportunity to position cross-sell of end-to-end services including global pricing, market access, marketing, patient support, and channel distribution to current and prospective pharmaceutical clients seeking integrated solutions.

Oncology focus Recent engagement with ASCO and leadership insights from EVERSANA Oncology Commercialization indicate a strong emphasis on oncology data translation and access strategies. Target potential partners developing cancer therapies that require robust commercialization, access programs, and payer engagement.

Commercialization scale With a revenue trajectory in the tens of millions and a growing client base highlighted by new product launches and collaborations (e.g., CAN-2409, ENSACOVE, SUBVENITE), there are expansion opportunities to elevate market access, payer strategies, and U.S. launch capabilities for mid to late-stage programs.

Strategic acquisitions EVERSANA’s acquisitions such as Waltz Health signal a push to diversify payer and purchasing leverage. This creates cross-sell opportunities with employers and health plans to integrate cost-effective pharmaceutical procurement alongside traditional commercialization services.

Global execution With a distributed tech stack and global service footprint, there is an opportunity to pitch scalable, tech-enabled commercialization solutions to mid-market and venture-backed biotech firms seeking rapid, compliant market access and patient-centric programs across multiple regions.